ID   Ma-Mel-86a
AC   CVCL_A221
SY   Ma-Mel_86a; Ma-Mel 86a; MaMel86a
DR   cancercelllines; CVCL_A221
DR   Cosmic; 1181752
DR   Cosmic; 1467777
DR   Cosmic; 1846677
DR   Cosmic; 2686483
DR   GEO; GSM109092
DR   GEO; GSM437028
DR   GEO; GSM2135603
DR   IGRhCellID; MaMel86a
DR   Progenetix; CVCL_A221
DR   Wikidata; Q54903860
RX   PubMed=16827748;
RX   PubMed=17311103;
RX   PubMed=20544847;
RX   PubMed=23348503;
RX   PubMed=27261508;
CC   HLA typing: A*01:01,24:02; B*08:01,15:01; C*03:03,07:01 (PubMed=27261508).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503; PubMed=27261508).
CC   Sequence variation: Mutation; HGNC; HGNC:1773; CDK4; Simple; p.Arg24His (c.71G>A); ClinVar=VCV000016929; Zygosity=Unspecified (PubMed=27261508).
CC   Sequence variation: Mutation; HGNC; HGNC:6840; MAP2K1; Simple; p.Pro193Ser (c.577C>T); dbSNP=rs1595884713; Zygosity=Unspecified (PubMed=27261508).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Asn212fs (c.633_645delAGATCCTCAGTTT); Zygosity=Unspecified (PubMed=27261508).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Trp (c.741_742delinsTT) (c.741_742CC>TT); ClinVar=VCV000437017; Zygosity=Unspecified (PubMed=27261508).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C4225; Cutaneous nodular melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A222 ! Ma-Mel-86b
OI   CVCL_C7TP ! Ma-Mel-86c
OI   CVCL_C7TQ ! Ma-Mel-86f
SX   Female
AG   34Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 23
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=17311103; DOI=10.1371/journal.pone.0000236; PMCID=PMC1794595;
RA   Ugurel S., Thirumaran R.K., Bloethner S., Gast A., Sucker A.,
RA   Mueller-Berghaus J., Rittgen W., Hemminki K., Becker J.C., Kumar R.,
RA   Schadendorf D.;
RT   "B-RAF and N-RAS mutations are preserved during short time in vitro
RT   propagation and differentially impact prognosis.";
RL   PLoS ONE 2:E236-E236(2007).
//
RX   PubMed=20544847; DOI=10.1002/gcc.20785;
RA   Gast A., Scherer D., Chen B.-W., Bloethner S., Melchert S., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Somatic alterations in the melanoma genome: a high-resolution
RT   array-based comparative genomic hybridization study.";
RL   Genes Chromosomes Cancer 49:733-745(2010).
//
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
//
RX   PubMed=27261508; DOI=10.1158/0008-5472.CAN-16-0008;
RA   Zhao F., Sucker A., Horn S., Heeke C., Bielefeld N., Schrors B.,
RA   Bicker A., Lindemann M., Roesch A., Gaudernack G., Stiller M.,
RA   Becker J.C., Lennerz V., Wolfel T., Schadendorf D., Griewank K.G.,
RA   Paschen A.;
RT   "Melanoma lesions independently acquire T-cell resistance during
RT   metastatic latency.";
RL   Cancer Res. 76:4347-4358(2016).
//